Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Target Raised at Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price objective hoisted by investment analysts at Cantor Fitzgerald from $67.00 to $87.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald‘s price objective would indicate a potential upside of 209.06% from the stock’s current price.

Several other research firms also recently commented on SUPN. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Weiss Ratings cut shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Piper Sandler initiated coverage on Supernus Pharmaceuticals in a research report on Wednesday. They issued an “overweight” rating and a $47.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $63.50.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $28.15 on Wednesday. Supernus Pharmaceuticals has a 52-week low of $27.97 and a 52-week high of $59.68. The company has a market cap of $1.64 billion, a P/E ratio of -36.56, a P/E/G ratio of 1.19 and a beta of 0.52. The stock’s 50-day simple moving average is $42.08 and its 200 day simple moving average is $47.15.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.14). The company had revenue of $208.60 million for the quarter, compared to analyst estimates of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 5.07% and a positive return on equity of 12.99%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the company posted ($0.80) earnings per share. As a group, equities analysts predict that Supernus Pharmaceuticals will post 1.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SUPN. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals during the second quarter worth $434,871,000. Bank of America Corp DE increased its stake in shares of Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the last quarter. Ashford Capital Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 5.4% in the 1st quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock valued at $33,360,000 after purchasing an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in shares of Supernus Pharmaceuticals by 2.0% in the 1st quarter. Rice Hall James & Associates LLC now owns 477,416 shares of the specialty pharmaceutical company’s stock valued at $24,678,000 after purchasing an additional 9,530 shares during the last quarter. Finally, Systematic Financial Management LP raised its holdings in shares of Supernus Pharmaceuticals by 23.6% during the 1st quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock worth $19,440,000 after buying an additional 71,853 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.